The Autoimmune Disease Partnering Terms and
Agreements report provides comprehensive understanding and unprecedented access
to the autoimmune disease partnering deals and agreements entered into by the
worlds leading healthcare companies
Description
The Autoimmune Disease Partnering Terms and
Agreements report provides comprehensive understanding and unprecedented access
to the autoimmune disease partnering deals and agreements entered into by the
worlds leading healthcare companies.
Trends in autoimmune disease partnering deals
Average deal terms for headline, upfront and
royalty by stage of development
Autoimmune disease partnering agreement structure
Autoimmune disease partnering contract documents
Top autoimmune disease deals by value
Most active autoimmune disease dealmakers
The Autoimmune Disease Partnering Terms and
Agreements report provides comprehensive understanding and unprecedented access
to the autoimmune disease partnering deals and agreements entered into by the
worlds leading healthcare companies.
The report provides a detailed understanding and
analysis of how and why companies enter autoimmune disease partnering deals.
The majority of deals are discovery or development stage whereby the licensee
obtains a right or an option right to license the licensors autoimmune disease
technology. These deals tend to be multicomponent, starting with collaborative
R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective
partner’s negotiated deals terms provides critical insight into the negotiation
process in terms of what you can expect to achieve during the negotiation of
terms. Whilst many smaller companies will be seeking details of the payments
clauses, the devil is in the detail in terms of how payments are triggered –
contract documents provide this insight where press releases do not.
This report contains a comprehensive listing of all
autoimmune disease partnering deals announced since 2010 including financial
terms where available, including over 700 links to online deal records of
actual autoimmune partnering deals as disclosed by the deal parties. In
addition, where available, records include contract documents as submitted to
the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an
orientation of autoimmune disease dealmaking and business activities. Chapter 1
provides an introduction to the report.
Chapter 2 provides an overview of the trends in
autoimmune disease dealmaking since 2010 covering trends by year, deal type,
stage of development, technology type and therapeutic indication. In addition
the chapter includes an analysis of financial deal terms by stage at signing
covering headline value, upfront payment, milestone payments and royalty rates.
Analysis includes median values and distribution of values for each stage of
development.
Chapter 3 provides a review of the leading
autoimmune disease deals since 2010. Deals are listed by headline value, signed
by big pharma, big biotech and most active of all biopharma companies. Where
the deal has an agreement contract published at the SEC a link provides online
access to the contract.
Chapter 4 provides a comprehensive listing of the
top 50 big pharma companies with a brief summary followed by a comprehensive
listing of autoimmune disease deals, as well as contract documents available in
the public domain. Where available, each deal title links via Weblink to an
online version of the actual contract document, providing easy access to each
contract document on demand.
Chapter 5 provides a comprehensive listing of the
top 50 big biotech companies with a brief summary followed by a comprehensive
listing of autoimmune disease deals, as well as contract documents available in
the public domain. Where available, each deal title links via Weblink to an
online version of the actual contract document, providing easy access to each
contract document on demand.
Chapter 6 provides a comprehensive directory of all
autoimmune disease partnering deals signed and announced since 2010 with a
contract attached. The chapter is organized by autoimmune deal type, stage of
development and technology type focus. Each deal title links via Weblink to an
online version of the deal record with the contract document.
Chapter 7 provides a comprehensive directory of all
autoimmune disease partnering deals signed and announced since 2010. The
chapter is organized by specific autoimmune therapy focus, including
inflammatory bowel disease, psoriasis, endometriosis, lupus, type 1 diabetes
and much more . Each deal title links via Weblink to an online version of the
deal record and where available, the contract document, providing easy access
to each contract document on demand.
In addition, a comprehensive appendix is provided
with each report of all autoimmune disease partnering deals signed and
announced since 2010. The appendices are organized by company A-Z, stage of
development at signing, deal type (collaborative R&D, co-promotion,
licensing etc) and technology type. Each deal title links via Weblink to an
online version of the deal record and where available, the contract document,
providing easy access to each contract document on demand.
The report also includes numerous tables and
figures that illustrate the trends and activities in autoimmune partnering and
dealmaking since 2010.
In conclusion, this report provides everything a
prospective dealmaker needs to know about partnering in the research,
development and commercialization of autoimmune disease technologies and
products.
Report scope
Autoimmune Disease Partnering Terms and Agreements
is intended to provide the reader with an in-depth understanding and access to
autoimmune disease trends and structure of deals entered into by leading
companies worldwide.
Autoimmune
Disease Partnering Terms and Agreements includes:
- Trends in autoimmune disease dealmaking in the biopharma industry since 2010
- Analysis of autoimmune disease deal structure
- Access to headline, upfront, milestone and royalty data
- Case studies of real-life autoimmune disease deals
- Access to over 700 autoimmune disease deals since 2010 and contract documents where available
- The leading autoimmune disease deals by value since 2010
- Most active autoimmune disease dealmakers since 2010
- The leading autoimmune disease partnering resources
In
Autoimmune Disease Partnering Terms and Agreements, the available contracts are
listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Stage of development at signing
- Deal component type
- Technology type
- Specific autoimmune therapy indication
Each deal title links via Weblink to an online
version of the deal record and where available, the contract document,
providing easy access to each contract document on demand.
The Autoimmune Disease Partnering Terms and
Agreements report provides comprehensive access to available deals and contract
documents for over 700 autoimmune disease deals. Analyzing actual contract
agreements allows assessment of the following:
- What are the precise autoimmune disease rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Benefits
Autoimmune Disease Partnering Terms and Agreements
provides the reader with the following key benefits:
- In-depth understanding of autoimmune disease deal trends since 2010
- Access to headline, upfront, milestone and royalty data
- Comprehensive access to over 700 actual autoimmune disease deals entered into by the world’s biopharma companies
- Detailed access to actual autoimmune disease contracts enter into by biopharma industries
- Insight into the terms included in an autoimmune disease agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Spanning over 1092 pages, “Autoimmune
Disease Partnering Terms and Agreements” report covers the Executive Summary,
Introduction, Trends in autoimmune disease dealmaking, Leading autoimmune
disease deals, Big pharma autoimmune disease deals, Big biotech autoimmune
disease deals, Autoimmune disease partnering contracts directory, Autoimmune
disease dealmaking by indication, Partnering resource center, Appendices.
For
further information on this report, please visit-
http://mrr.cm/4QJ
Find all Healthcare Reports
at: http://www.marketresearchreports.com/healthcare
No comments:
Post a Comment
Note: only a member of this blog may post a comment.